Global Circumferential and Radial Strain Among Patients With Immune Checkpoint Inhibitor Myocarditis.
cardiovascular risk stratification
immune checkpoint inhibitors
myocarditis
strain modalities survival analysis
Journal
JACC. Cardiovascular imaging
ISSN: 1876-7591
Titre abrégé: JACC Cardiovasc Imaging
Pays: United States
ID NLM: 101467978
Informations de publication
Date de publication:
11 2022
11 2022
Historique:
received:
22
11
2021
revised:
25
05
2022
accepted:
22
06
2022
entrez:
10
11
2022
pubmed:
11
11
2022
medline:
15
11
2022
Statut:
ppublish
Résumé
Global circumferential strain (GCS) and global radial strain (GRS) are reduced with cytotoxic chemotherapy. There are limited data on the effect of immune checkpoint inhibitor (ICI) myocarditis on GCS and GRS. This study aimed to detail the role of GCS and GRS in ICI myocarditis. In this retrospective study, GCS and GRS from 75 cases of patients with ICI myocarditis and 50 ICI-treated patients without myocarditis (controls) were compared. Pre-ICI GCS and GRS were available for 12 cases and 50 controls. Measurements were performed in a core laboratory blinded to group and time. Major adverse cardiovascular events (MACEs) were defined as a composite of cardiogenic shock, cardiac arrest, complete heart block, and cardiac death. Cases and controls were similar in age (66 ± 15 years vs 63 ± 12 years; P = 0.20), sex (male: 73% vs 61%; P = 0.20) and cancer type (P = 0.08). Pre-ICI GCS and GRS were also similar (GCS: 22.6% ± 3.4% vs 23.5% ± 3.8%; P = 0.14; GRS: 45.5% ± 6.2% vs 43.6% ± 8.8%; P = 0.24). Overall, 56% (n = 42) of patients with myocarditis presented with preserved left ventricular ejection fraction (LVEF). GCS and GRS were lower in myocarditis compared with on-ICI controls (GCS: 17.5% ± 4.2% vs 23.6% ± 3.0%; P < 0.001; GRS: 28.6% ± 6.7% vs 47.0% ± 7.4%; P < 0.001). Over a median follow-up of 30 days, 28 cardiovascular events occurred. A GCS (HR: 4.9 [95% CI: 1.6-15.0]; P = 0.005) and GRS (HR: 3.9 [95% CI: 1.4-10.8]; P = 0.008) below the median was associated with an increased event rate. In receiver-operating characteristic (ROC) curves, GCS (AUC: 0.80 [95% CI: 0.70-0.91]) and GRS (AUC: 0.76 [95% CI: 0.64-0.88]) showed better performance than cardiac troponin T (cTnT) (AUC: 0.70 [95% CI: 0.58-0.82]), LVEF (AUC: 0.69 [95% CI: 0.56-0.81]), and age (AUC: 0.54 [95% CI: 0.40-0.68]). Net reclassification index and integrated discrimination improvement demonstrated incremental prognostic utility of GRS over LVEF (P = 0.04) and GCS over cTnT (P = 0.002). GCS and GRS are lower in ICI myocarditis, and the magnitude of reduction has prognostic significance.
Sections du résumé
BACKGROUND
Global circumferential strain (GCS) and global radial strain (GRS) are reduced with cytotoxic chemotherapy. There are limited data on the effect of immune checkpoint inhibitor (ICI) myocarditis on GCS and GRS.
OBJECTIVES
This study aimed to detail the role of GCS and GRS in ICI myocarditis.
METHODS
In this retrospective study, GCS and GRS from 75 cases of patients with ICI myocarditis and 50 ICI-treated patients without myocarditis (controls) were compared. Pre-ICI GCS and GRS were available for 12 cases and 50 controls. Measurements were performed in a core laboratory blinded to group and time. Major adverse cardiovascular events (MACEs) were defined as a composite of cardiogenic shock, cardiac arrest, complete heart block, and cardiac death.
RESULTS
Cases and controls were similar in age (66 ± 15 years vs 63 ± 12 years; P = 0.20), sex (male: 73% vs 61%; P = 0.20) and cancer type (P = 0.08). Pre-ICI GCS and GRS were also similar (GCS: 22.6% ± 3.4% vs 23.5% ± 3.8%; P = 0.14; GRS: 45.5% ± 6.2% vs 43.6% ± 8.8%; P = 0.24). Overall, 56% (n = 42) of patients with myocarditis presented with preserved left ventricular ejection fraction (LVEF). GCS and GRS were lower in myocarditis compared with on-ICI controls (GCS: 17.5% ± 4.2% vs 23.6% ± 3.0%; P < 0.001; GRS: 28.6% ± 6.7% vs 47.0% ± 7.4%; P < 0.001). Over a median follow-up of 30 days, 28 cardiovascular events occurred. A GCS (HR: 4.9 [95% CI: 1.6-15.0]; P = 0.005) and GRS (HR: 3.9 [95% CI: 1.4-10.8]; P = 0.008) below the median was associated with an increased event rate. In receiver-operating characteristic (ROC) curves, GCS (AUC: 0.80 [95% CI: 0.70-0.91]) and GRS (AUC: 0.76 [95% CI: 0.64-0.88]) showed better performance than cardiac troponin T (cTnT) (AUC: 0.70 [95% CI: 0.58-0.82]), LVEF (AUC: 0.69 [95% CI: 0.56-0.81]), and age (AUC: 0.54 [95% CI: 0.40-0.68]). Net reclassification index and integrated discrimination improvement demonstrated incremental prognostic utility of GRS over LVEF (P = 0.04) and GCS over cTnT (P = 0.002).
CONCLUSIONS
GCS and GRS are lower in ICI myocarditis, and the magnitude of reduction has prognostic significance.
Identifiants
pubmed: 36357131
pii: S1936-878X(22)00405-3
doi: 10.1016/j.jcmg.2022.06.014
pmc: PMC10334352
mid: NIHMS1899183
pii:
doi:
Substances chimiques
Immune Checkpoint Inhibitors
0
Troponin T
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1883-1896Subventions
Organisme : NHLBI NIH HHS
ID : K24 HL150238
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL137562
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL130539
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NHLBI NIH HHS
ID : T32 HL007208
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2022 American College of Cardiology Foundation. All rights reserved.
Déclaration de conflit d'intérêts
Funding Support and Author Disclosures This work was supported by the National Institutes of Health (P30CA008748 to DG and CLC; R01HL137562, R01HL130539; and T32HL007208-39 to DAZ). Dr Mahmood has received consultancy fees from Health and Wellness Partners, OMR Globus, Alpha Detail, and Opinion Research Team. Dr Zhang is consultant for MERCK. Dr Sullivan has served as a consultant for Merck and Novartis. Dr Heinzerling has received consultancy, advisory board, and speaker fees from Merck Sharp & Dohme, BMS, Roche, Novartis, Amgen, Sun Pharma, Pierre Fabre, and CureVac. Dr Gavira has received research support from Amgen. Dr Zubiri has served as a consultant to Merck and is supported by a SEOM (Sociedad Española de Oncología Médica) grant. Dr Yang has received research funding from CSL Behring. Dr Nohria has received research support from Amgen and has been a consultant for Takeda Oncology, Boehringer Ingelheim, and AstraZeneca; and he has received support from the Catherine Geoff Fitch fund and Gelb Master Clinician Fund. Dr Fradley has received consulting fees from AstraZeneca and Abbott and has received a research grant from Medtronic. Dr Neilan is supported by a gift from A. Curt Greer and Pamela Kohlberg and from Christina and Paul Kazilionis, the Michael and Kathryn Park Endowed Chair in Cardiology, and a Hassenfeld Scholar Award; has received advisory fees from AbbVie, Amgen, C4 Therapeutics, H3-Biomedicine, Genentech, Roche, BMS, and Intrinsic Imaging; has received grant funding from AstraZeneca; and he is also supported by grants from the National Institutes of Health/National Heart, Lung, and Blood Institute (R01HL130539, R01HL137562, K24HL150238). All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Références
J Cardiovasc Magn Reson. 2020 Dec 14;22(1):87
pubmed: 33308262
J Am Coll Cardiol. 2017 Oct 17;70(16):1964-1976
pubmed: 29025553
J Am Coll Cardiol. 2014 Jul 1;63(25 Pt A):2751-68
pubmed: 24703918
Oncologist. 2018 Aug;23(8):879-886
pubmed: 29802219
J Am Coll Cardiol. 2017 Aug 22;70(8):942-954
pubmed: 28818204
J Am Soc Echocardiogr. 2005 Dec;18(12):1440-63
pubmed: 16376782
Curr Cardiol Rep. 2018 Sep 26;20(11):114
pubmed: 30259175
Eur J Heart Fail. 2014 Mar;16(3):300-8
pubmed: 24464946
J Am Soc Echocardiogr. 2013 Feb;26(2):185-91
pubmed: 23218891
Eur Heart J Cardiovasc Imaging. 2015 Aug;16(8):871-81
pubmed: 25711353
J Am Coll Cardiol. 2017 Oct 17;70(16):1977-1987
pubmed: 29025554
J Am Coll Cardiol. 2018 Apr 24;71(16):1755-1764
pubmed: 29567210
Am J Cardiovasc Pathol. 1987 Jan;1(1):3-14
pubmed: 3455232
Nat Rev Drug Discov. 2019 Nov;18(12):899-900
pubmed: 31780841
PLoS One. 2021 Feb 19;16(2):e0246764
pubmed: 33606757
J Am Heart Assoc. 2020 Jan 21;9(2):e015400
pubmed: 31959033
Nat Commun. 2020 Jul 30;11(1):3801
pubmed: 32732879
Heart. 2010 Jul;96(14):1137-41
pubmed: 20511624
Scand J Public Health. 2011 Jun;39(4):439-41
pubmed: 21270137
Eur Heart J Cardiovasc Imaging. 2013 Feb;14(2):175-82
pubmed: 22802431
Cardiovasc Pathol. 2012 Jul-Aug;21(4):245-74
pubmed: 22137237
Eur Heart J. 2022 Jan 31;43(4):316-329
pubmed: 34389849
J Am Coll Cardiol. 2020 Feb 11;75(5):467-478
pubmed: 32029128
J Am Coll Cardiol. 2021 Mar 30;77(12):1503-1516
pubmed: 33766256
BMC Cancer. 2021 Jan 7;21(1):38
pubmed: 33413213
J Am Soc Echocardiogr. 2015 Jan;28(1):1-39.e14
pubmed: 25559473
Eur Heart J. 2020 May 7;41(18):1733-1743
pubmed: 32112560
Echocardiography. 2018 Jul;35(7):922-934
pubmed: 29603386
Eur J Echocardiogr. 2011 Dec;12(12):945-52
pubmed: 21965152
Curr Treat Options Cardiovasc Med. 2019 Jun 8;21(7):32
pubmed: 31175469
Echocardiography. 2012 Aug;29(7):810-7
pubmed: 22497597
Radiology. 2021 Dec;301(3):602-609
pubmed: 34581628
Int J Cardiovasc Imaging. 2013 Feb;29(2):275-84
pubmed: 22736428
Nat Rev Cardiol. 2021 Mar;18(3):169-193
pubmed: 33046850
Circulation. 2018 Sep 11;138(11):1088-1099
pubmed: 29764898
Eur Heart J. 2013 Sep;34(33):2636-48, 2648a-2648d
pubmed: 23824828